பெத் சீடன்பெர்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பெத் சீடன்பெர்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பெத் சீடன்பெர்க் Today - Breaking & Trending Today

Capsida Biotherapeutics Debuts with $140 Million of Capital


Capsida Biotherapeutics Debuts with $140 Million of Capital
- Versant, Westlake Village BioPartners launch next-generation gene therapy company with $50 million Series A -
- Collaboration with AbbVie provides $90 million in up front and equity investment capital to create tissue-targeted gene therapies for three CNS disease targets -
News provided by
Share this article
Share this article
THOUSAND OAKS, Calif., April 29, 2021 /PRNewswire/ Versant Ventures and Westlake Village BioPartners today announced the emergence from stealth mode of Capsida Biotherapeutics Inc., a biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases. In addition to a $50 million Series A commitment from the two firms, Capsida also announced a multi-year strategic collaboration and option agreement with AbbVie that provides $90 million in up front and equity invest ....

Thousand Oaks , United States , Eric Karran , Los Angeles , Beth Seidenberg , Robert Cuddihy , Viviana Gradinaru , Capsida Biotherapeutics , Clare Ozawa , Chrissy Chen Institute For Neuroscience At Caltech , Capsida Biotherapeutics Inc , Heritage Medical Research Institute Investigator , Westlake Village Biopartners , Biological Engineering , Cellular Neuroscience , Chrissy Chen Institute , Vice President , Neuroscience Discovery , Greater Los Angeles , Village Biopartners , ஆயிரம் ஓக்ஸ் , ஒன்றுபட்டது மாநிலங்களில் , லாஸ் ஏஞ்சல்ஸ் , பெத் சீடன்பெர்க் , தெளிவு ஒஸாவ , கிறிஸி சென் நிறுவனம் க்கு நரம்பியல் இல் கால்டெக் ,

Newbury Park Biotech Startup Lands $140 Million Investment | San Fernando Valley Business Journal


 
Newbury Park biotech startup Capsida Biotherapeutics on Thursday emerged from stealth mode with a whopping $140 million in capital.
“Stealth mode,” meaning a company that avoids publicity while furthering its research, ended with a $50 million Series A round led by Westlake Village BioPartners in Westlake Village and Bay Area Versant Ventures, coupled with a $90 million collaboration with AbbVie in Chicago, Capsida said in a statement.
The company plans to use capital to expand its 50-member team to about 100 scientists this year and pursue other strategic and financial investment opportunities.
Capsida focuses on creating tissue-targeted gene therapies for multiple types of diseases, the company said in a statement. These therapies are developed using adeno-associated virus, or AAV engineering, and a genetic cargo development platform. The technology generates modified capsids, or a “cage” that protects a viral genome from environmental conditions, to b ....

United States , Los Angeles , Beth Seidenberg , Robert Cuddihy , Viviana Gradinaru , Newbury Park , Westlake Village Biopartners , Westlake Village , Bay Area Versant Ventures , Greater Los Angeles , Village Biopartners , ஒன்றுபட்டது மாநிலங்களில் , லாஸ் ஏஞ்சல்ஸ் , பெத் சீடன்பெர்க் , நியூபரி பூங்கா , வெஸ்ட்லேக் கிராமம் , அதிகமானது லாஸ் ஏஞ்சல்ஸ் ,